Nonsustained ventricular tachycardia: Current evaluation and management

Annals of Noninvasive Electrocardiology

Volumn 2, Issue 1, 1997, Pages 79-91

  Daubert, James P ^a   Kim, Chee H ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

antiarrhythmic agents; implantable defibrillator; myocardial infarction; sudden death; ventricular tachycardia

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

CLINICAL EXAMINATION; DEFIBRILLATION; DEFIBRILLATOR; HEART VENTRICLE TACHYCARDIA; HUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIGNAL AVERAGED ELECTROCARDIOGRAPHY;

EID: 0030939378     PISSN: 1082720X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1542-474X.1997.tb00312.x     Document Type: Review

References (129)

1. Lown B. Sudden cardiac death-1978. Circulation 1979; 60: 1593-1599.
2. Bigger JT, Weld FM. Analysis of prognostic significance of ventricular arrhythmias after myocardial infarction - shortcomings of the Lown grading system. British Heart J 1981;45:717-724.
3. Moss AJ, DeCamilla J, Mietlowski W, et al. Prognostic grading and significance of ventricular ectopic beats with respect to sudden death in the late post infarction period. Circulation 1975; 52:111-204-111-209.
4. Bigger JT Jr, Fleiss JL, Rolnitzky LM. Prevalence, characteristics and significance of ventricular tachycardia detected by 24-hour continuous electrocardiographic recordings in the late hospital phase of acute myocardial infarction. Am J Cardiol 1986;58:1151-1160.
5. Kennedy HL, Whitlock JA, Sprague MK, et al. Long-term follow-up of asymptomatic healthy subjects with frequent and complex ventricular ectopy. N Engl J Med 1985;312: 193-197.
6. Bigger JT Jr, Fleiss JL, Kleiger R, et al. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the two years after myocardial infarction. Circulation 1984; 69:250-258.
7. de Bakker JM, van Capelle FJ, Janse MJ, et al. Macroreentry in the infarctd human heart: The mechanism of ventricular tachycardias with a "focal" activation pattern. J Am Coll Cardiol 1991; 18:1005-10014.
8. Stevenson WG, Sager PT, Friedman PL. Entrainment techniques for mapping atrial and ventricular tachycardias. J Cardiovasc Electrophysiol 1995; 6:201-216.
9. Downar E, Kimber S, Harris L, et al. Endocardial mapping of ventricular tachycardia in the intact human heart. II. Evidence for multiuse reentry in a functional sheet of surviving myocardium. J Am Coll Cardiol 1992; 20:869-878.
10. Waldecker B, Coromilas J, Saltman AE, et al. Overdrive stimulation of functional reentrant circuits causing ventricular tachycardia in the infarcted canine heart. Resetting and entrainment. Circulation 1993; 87:1286-1305.
11. El-Sherif N. Experimental models of reentry, antiarrhythmic, and proarrhythmic actions of drugs. Complexities galore: [editorial; comment] [see comments]. Circulation 1991;84:1871-1875.
12. Restivo M, Yin H, Caref EB, et al. Reentrant arrhythmias in the subacute infarction period. The proarrhythmic effect of flecainide acetate on functional reentrant circuits. Circulation 1995;91:1236-1246.
13. Blanck Z, Jazayeri M, Dhala A, et al. Bundle branch reentry: A mechanism of ventricular tachycardia in the absence of myocardial or valvular dysfunction. J Am Coll Cardiol 1993;22:1718-1722.
14. Chinushi M, Aizawa Y, Masani F, et al. Possible intramural site of reentrant circuit in ventricular tachycardia of nonischemic cause. Pre and intraoperative mapping studies. Jpn Heart] 1992;33:505-512.
15. de Paola AA, Horowitz LN, Miyamoto MH, et al. Angiographie and electrophysiologic substraes of ventricular tachycardia in chronic Chagasic myocarditis. Am J Cardiol 1990; 65:360-363.
16. Winters SL, Cohen M, Greenberg S, et al. Sustained ventricular tachycardia associated with sarcoidosis: Assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy, and an implantable antitachycardia device. J Am Coll Cardiol 1991; 18:937-943.
17. Saumarez RC, Slade AK, Grace AA, et al. The significance of paced electrogram fractionation in hypertrophie cardiomyopathy. A prospective study. Circulation 1995; 91:2762-2768.
18. Silka MJ, Park JK. Mechanisms in current management of ventricular tachycardia in children. Heart Dis Stroke 1994; 3:372-376.
19. Kirn YH, Leitch JW, Klein GJ, et al. Catheter ablation of idiopathic exercise-induced right bundle branch block and left axis deviation ventricular tachycardia. Can J Cardiol 1991;7:189-192.
20. Kottkamp H, Chen X, Hindricks G, et al. Idiopathic left ventricular tachycardia: New insights into electrophysiological characteristics and radiofrequency catheter ablation. Pacing Clin Electrophysiol 1995; 18:1285-1297.
21. Wu G, Littmann L, Svenson RH, et al. Computerized three-dimensional activation mapping study of spontaneous ventricular arrhythmias during acute myocardial ischemia in dogs. Evidence against macroreentrant mechanism. J of Electrocard 1995;28:115-130.
22. Peters RW, Kim HJ, Buser GA, et al. Ischemically mediated sustained monomorphic ventricular tachycardia. Resolution with anti-ischemic therapy. Chest 1993; 104:1613-1614.
23. Wolfe CL, Nibley C, Bhandari A, et al. Polymorphous ventricular tachycardia associated with acute myocardial infarction. Circulation 1991;84:1543-1551.
24. Pogwizd SM, Hoyt RH, Saffitz JE, et al. Reentrant and focal mechanisms underlying ventricular tachycardia in the human heart. Circulation 1992; 86:1872-1887.
25. Pogwizd SM. Nonreentrant mechanisms underlying spontaneous ventricular arrhythmias in a model of nonischemic heart failure in rabbits. Circulation 1995;92:1034-1048.
26. Lerman BB, Stein K, Engelstein ED, et al. Mechanism of repetitive monomorphic ventricular tachycardia. Circulation 1995;92:421-429.
27. Ciaccio EJ, Wit AL, Scheinman MM, et al. Prediction of the location and time of spontaneous termination of reentrant ventricular tachycardia for radiofrequency catheter ablation therapy. J of Electrocard 1995;28:165-173.
28. Callans DJ, Marchlinski FE. Dissociation of termination and prevention of inducibility of sustained ventricular tachycardia with infusion of procainamide: Evidence for distinct mechanisms. J Am Coll Cardiol 1992; 19:111-117.
29. El-Sherif N, Hope RR, Scherlag BJ, et al. Reentrant ventricular arrhythmias in the late myocardial infarction period. 2. Patterns of initiation and termination of re-entry. Circulation 1977; 55:702-719.
30. Frame LH, Rhee EK. Spontaneous termination of reentry after one cycle or short nonsustained runs. Role of oscillations and excess dispersion of refractoriness. Circulation Research 1991; 68:493-502.
31. Duff HJ, Mitchell LB, Gillis AM, et al. Electrocardiographic correlates of spontaneous termination of ventricular tachycardia in patients with coronary artery disease. Circulation 1993;88:1054-1062.
32. Denes P. Morphologic characteristics of nonsustained ventricular tachycardia detected during Holter monitoring associated with atherosclerotic coronary artery disease. Am J Cardiol 1993;71:57-62.
33. Buxton AE, Lee KL, DiCarlo L, et al. Nonsustained ventricular tachycardia in coronary artery disease: Relation to inducible sustained ventricular tachycardia. MUSTT Investigators. Annals of Internal Medicine 1996; 125:35-39.
34. Fei H, Frame LH. d-Sotlol terminates reentry by two mechanisms with different dependence on the duration of the excitable gap. J Pharm & Exper Therap 1996;277:174-185.
35. Buxton AE, Josephson ME, Marchlinski FE, et al. Polymorphic ventricular tachycardia induced by programmed stimulation: Response to procainamide. J Am Coll Cardiol 1993;21:90-98.
36. Stevenson WG, Weiss J, Stevenson LW, et al. Facilitation of ventricular tachycardia initiation by procainamide during programmed venticular stimulation in patients with heart failure. J Electrocardiol 1990; 23:77-83.
37. Coromilas J, Saltman AE, Waldecker B, et al. Electrophysiological effects of flecainide on anisotropic conduction and reentry in infarcted canine hearts. Circulation 1995; 91: 2245-2263.
38. Schulze RA Jr, Strauss HW, Pitt B. Sudden death in the year following myocardial infarction. Relation to ventricular premature contractions in the late hospitals phase and left ventricular ejection fraction. Am J Med 1977; 62:192-199.
39. Mukhaiji J, Rude RE, Poole WK, et al. Risk factors for sudden death after acute myocardial infarction: Two year follow-up. Am J Cardiol 1984; 54:31-36.
40. Ruberman W, Weinblatt E, Goldberg JD, et al. Ventricular premature beats and mortality after myocardial infarction. N Eng J Med 1977;297:750-757.
41. Ruberman W, Weinblatt E, Goldberg JD, et al. Ventricular premature complexes and sudden death after myocardial infarction. Circulation 1981;64:297-305.
42. Follansbee WP, Michelson EL, Morganroth J. Nonsustained ventricular tachycardia in ambulatory patients: Characteristics and association with sudden cardiac death. Ann Int Med 1980; 92:741-747.
43. The Coronary artery Bypass Graft (CABG) Patch Trial. Progress in Cardiovascular Diseases 1993; 36:97-114.
44. Holmes DR, Davis KB, Mock MB. The effect of medical and surgical treatment on subsequent sudden cardiac death in patients with coronary artery disease: A report from the Coronary Artery Surgery Study. Circulation 1986; 73:1254-1263.
45. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.
46. Buxton AE, Fisher JD, Josephson ME, et al. Prevention of sudden death in patients with coronary artery disease: The Multicenter Unsustained Tachycardia Trial (MUSTT). Prog Cardiovasc Dis 1993; 36:215-226.
47. Kadish A, Schmaltz S, Calkins H, et al. Management of nonsustained ventricular tachycardia guided by electrophysiological testing. Pacing Clin Eleclrophysiol 1993; 16: 1037-1050.
48. Hammill SC, Trusty JM, Wood DL, et al. Influence of ventricular function and presence or absence of coronary artery disease on results of electrophysiologic testing for asymptomatic nonsustained ventricular tachycardia. Am J Cardiol 1990; 65:722-728.
49. Manolis AS, Estes NAd. Value of programmed ventricular stimulation in the evaluation and management of patients with nonsustained ventricular tachycardia associated with coronary artery disease. Am J Cardiol 1990;65:201-205.
50. Fananapazir L, Chang AC, Epstein SE, et al. Prognostic determinants in hypertrophie cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical Holler, hemodynamic, and electrophysiological findings. Circulation 1992; 86:730-740.
51. Bhadha K, Marchlinski FE, Iskandrian AS. Ventricular tachycardia in patients without structural heart disease. Am Heart] 1993;126:1194-1198.
52. Wen MS, Yeh SJ, Wang CC, et al. Radiofrequency ablation therapy in idiopathic left ventricular tachycardia with no obvious structural heart disease. Circulation 1994; 89: 1690-1696.
53. Fontaine G. Arrhythmogenic right ventricular dysplasia. Curr Opin Cardiol 1995; 10:16-20.
54. Kullo IJ, Edwards WD, Seward JB. Right ventricular dysplasia: The Mayo Clinic experience. Mayo Clinic Proceedings 1995; 70:541-548.
55. Marcus FI, Fontaine G. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: A review. PACE 1995; 18:1298-1314.
56. Metzger JT, de Chillou C, Cheriex E, et al. Value of the 12-lead electrocardiogram in arrhythmogenic right ventricular dysplasia, and absence of correlation with echocardiographic findings. Am J Cardiol 1993; 72:964-967.
57. Shen WK, Edwards WD, Hammill SC, et al. Sudden unexpected nontraumatic death in 54 young adults: A 30-year population-based study. Am J Cardiol 1995;76:148-152.
58. Solenthaler M, Ritter M, Candinas R, et al. Arrhythmogenic right ventricular dysplasia in identical twins. Am J Cardiol 1994; 74:303-304.
59. Zipes DP, Jalife J. Cardiac Electrophysiology: From Cell to Bedside. Philadelphia, WB Saunders, 1995, pp. 780-788.
60. Daoud E, Morady F. Catheler ablation of ventricular tachycardia. Current Opinion in Cardiology 1995; 10:21-25.
61. Gomes JA, Winters SL, Stewart D, et al. A new noninvasive index to predict sustained ventricular tachycardia and sudden death in the first year after myocardial infarction: Based on signal-averaged electrocardiogram, radionuclide ejection fraction and Holler monitoring. J Am Coll Cardiol 1987; 10:349-357.
62. Kuchar DL, Thorburn CW, Sammel NL. Prediction of serious arrhythmic events after myocardial infarction: Signalaveraged electrocardiogram, Holler monitoring and radionuclide ventriculography. J Am Coll Cardiol 1987; 9:531-538.
63. Turitlo G, Ahuja RK, Bekheil S, el al. Incidence and prediclion of induced ventricular tachyarrhythmias in idiopathic dilated cardiomyopathy. Am J Cardiol 1994; 73:770-773.
64. Mancini DM, Wong KL, Simson MB. Prognostic value of an abnormal signal-averaged electrocardiogram in patients with nonischemic congestive cardiomyopathy [see comments]. Circulation 1993;87:1083-1092.
65. Kleiger RE, Miller JP, Bigger JT Jr, et al. Decreased heart rate variability and ils associalion with increased mortality after acute myocardial infarction. Am J Cardiol 1987; 59: 256-262.
66. Kjellgren O, Gomes JA. Heart rate variability and baroreflex sensitivity in myocardial infarction. Am Heart J 1993; 125:204-215.
67. Osterziel KJ, Hanlein D, Willenbrock R, et al. Baroreflex sensitivity and cardiovascular mortality in patients with mild to moderate heart failure. Br Heart J 1995; 73:517-522.
68. La Rovere MT, Mortara A, Schwartz PJ. Baroreflex sensitivity. J Cardiovasc Electro 1995; 6:761-774.
69. Vanoli E, De Ferrari GM, Stramba-Badiale M, et al. Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction. Circulation Research 1991;68:1471-1481.
70. Bigger JT Jr, La Rovere MT, Steinman RC, et al. Comparison of baroreflex sensitivity and heart period variability after myocardial infarction. J Am Coll Cardiol 1989; 14: 1511-1518.
71. Schwartz PJ, Billman GE, Stone HL. Autonomie mechanisms in ventricular fibrillation induced by myocardial ischemia during exercise in dogs with healed myocardial infarction. An experimental preparation for sudden cardiac death. Circulation 1984; 69:790-800.
72. Nearing BD, Huang AH, Verrier RL. Dynamic tracking of cardiac vulnerability by complex demodulation of the T wave. Science 1991;252:437-440.
73. Rosenbaum DS, Jackson LE, Smith JM, et al. Electrical alternans and vulnerability to ventricular arrhythmias. N Eng J Med 1994; 330:235-241.
74. Kowey PR, Waxman HL, Greenspon A, et al. Value of electrophysiologic testing in patients with previous myocardial infarction and nonsustained ventricular tachycardia. Philadelphia Arrhythmia Group. Am J Cardiol 1990; 65:594-598.
75. Veltri EP, Platia EV, Griffith LS, et al. Programmed electrical stimulation and long-term follow-up in asymptomatic, nonsustained ventricular tachycardia. Am J Cardiol 1985; 56:309-314.
76. Sulpizi AM, Friehling TD, Kowey PR. Value of electrophysiologic testing in patients with nonsustained ventricular tachycardia. Am J Cardiol 1987;59:841-845.
77. Hernandez M, Taylor J, Marinchak R, et al. Outcome of patients with nonsustained ventricular tachycardia and severely impaired ventricular function who have negative electrophysiologic studies. Am Heart J 1995; 129:492-496.
78. Kowey PR, Taylor JE, Marinchak RA, et al. Does programmed stimulation really help in the evaluation of patients with nonsustained ventricular tachycardia? Results of a meta-analysis. Am Heart J 1992; 123:481-485.
79. Poll DS, Marchlinski FE, Buxton AE, et al. Usefulness of programmed stimulation in idiopathic dilated cardiomyopathy. Am J Cardiol 1986; 58:992-997.
80. Chen X, Shenasa M, Borggrefe M, el al. Role of programmed ventricular stimulation in patients with idiopathic dilated cardiomyopathy and documented sustained ventricular tachyarrhythmias: Inducibility and prognostic value in 102 patients. Eur Heart J 1994; 15:76-82.
81. McKenna WJ, Sadoul N, Slade AK, et al. The prognostic significance of nonsustained ventricular tachycardia in hypertrophie cardiomyopathy [editorial; comment]. Circulation 1994;90:3115-3117.
82. Gardin LL, Nanton MA, Hanna BD. Ambulatory monitoring of the sudden death of an adolescent with hypertrophie cardiomyopathy. Can J Cardiol 1994; 10:548-550.
83. Hine L, Laird N, Hewitt P. Meta-analysis of empiric chronic antiarrhythmic therapy after myocardial infarction. J Am Med Ass 1989; 262:3037-3040.
84. Chamberlain DA, Jewitt DE, Julian DG, et al. Oral mexilet-ine in high-risk patients after myocardial infarction. Lancet 1980;2:1324-1327.
85. Preliminaly report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989; 321:406-412.
86. Epstein AE, Hallstrom AP, Rogers WJ, et al. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). JAMA 1993;270:2451-2455.
87. Goldstein S, Brooks MM, Ledingham R, et al. Association between ease of suppression of ventricular arrhythmia and survival. Circulation 1995; 91:79-83.
88. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med 1992; 327: 227-233.
89. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 1993;270:1589-1595.
90. Yusuf S, Venkatesh G, Teo KK. Critical review of the approaches to the prevention of sudden death. Am J Cardiol 1993;72:51F-58F.
91. Burkart F. Value and risk of class I and III antiarrhythmic drugs. PACE 1994; 17:467-472.
92. A randomized trial of propranolol in patients with acute myocardial infarction. (Beta-blocker Heart Attack Trial Research Group) JAMA 1982;247:1707-1714.
93. Lichstein E, Marganroth J, Harris R, et al. Effect of propranolol on ventricular arrhythmia: The Beta-Blocker Heart Attack Trial Experience. Circulation 1983; 67:1-5-1-10.
94. Kendall MJ, Lynch KP, Hjalmarson A, Kjekshus J. Beta-blockers and sudden cardiac death. Ann Intern Med 1995; 123:358-367.
95. Kennedy HL, Brooks MM, Barker AH, et al. Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. Am J Cardiol 1994; 74:674-680.
96. Design of the Beta-Blocker Evaluation Survival Trial (BEST). The BEST Steering Committee. Am J Cardiol 1995; 75:1220-1223.
97. Julian DG, Jackson FS, Prescott RJ, et al. Controlled trial of sotalol for one year after myocardial infarction. The Lancet 1982; 1:1742-1747.
98. Waldo AL, Camm AJ, de Ruyter H, et al. Survival with left ventricular dysfunction after myocardial infarction: Rationale, design, and methods (the SWORD trial). Am J Cardiol 1995; 75: 1023-1027.
99. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996; 348:7-12.
100. Connolly SJ, Gent M, Roberts RS, et al. Canadian Implantable Defibrillator Study (CIDS): Study design and organization. CIDS Co-Investigators. Am J Cardiol 1993; 72: 103F-108F.
101. Camm AJ, Julian D, Janse G, et al. The European Myocardial Infarct Amiodarone Trial (EMIAT). EMIAT Investigators. Am J Cardiol 1993;72:95F-98F.
102. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestiue heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995; 333:77-82.
103. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994;344:493-498.
104. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, et al. Effect of amiodarone on mortality after myocardial infarction: A double-blind, placebo-controlled, pilot study. J Am Coll Cardiol 1992;211:1056-1062.
105. Nicklas JM, McKenna WJ, Stewart RA, et al. Prospective, double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. Am Heart J 1991; 122:1016-1021.
106. Burkart F, Pfisterer M, Kiowski W, et al. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll.Cardiol 1990; 16:1711-1718.
107. Cairns JA, Connolly SJ, Roberts R, et al. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT): Rationale and protocol. CAMIAT Investigators. Am J Cardiol 1993;72:87F-94F.
108. Connolly SJ. Preliminary results of Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT): Personal Communication, 1996.
109. Pratt CM, Greenway PS, Schoenfeld MH, et al. Exploration of the precision of classifying sudden cardiac death. Implications for the interpretation of clinical trials. Circulation 1996; 93:519-524.
110. Hinkle LE, Thaler JT. Clinical classification of cardiac deaths. Circulation 1982; 65:457.
111. Klein H: Personal Communication re: The European Myocardial Infarct Amiodarone Trial (EMIAT) preliminary results as presented orally at American College of Cardiology Meeting, March 1996.
112. Schwartz PJ, Camm AJ, Frangin G, et al: Does amiodarone reduce sudden death and cardiac mortality after myocardial infarction? The European Myocardial Infarct Amiodarone Trial (EMIAT). Eur Heart J 1994; 15:620-624.
113. Steinbeck G, Andresen D, Bach P, et al. A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta-blocker therapy in patients with symptomatic, sustained ventricular tachyarrhythmias [published erratum appears in N Engl J Med 1993 Jan 7;328(1):71]. N Engl JMed 1992; 327:987-992.
114. Young GD, Kerr CR, Mohama R, et al. Efficacy of sotalol guided by programmed electrical stimulation for sustained ventricular arrhythmias secondary to coronary artery disease. Am J Cardiol 1994; 73:677-682.
115. Lazzara R. Resulls of Holler ECG guided therapy for ventricular arrhythmias: The ESVEM trial. PACE 1994; 17: 473-477.
116. Fisher JD, Kim SG, Ferrick KJ, et al. Serial elctrophysiologic-pharmacologic studies for the control of ventricular arrhythmias. Coronary Artery Disease 1994; 5:653-664.
117. Prystowsky EN. Electrophysiologic-electropharmacologic testing in patients with ventricular arrhythmias. PACE 1988; 11:225-251.
118. Wilber DJ, Olshansky B, Moran JF, et al. Electrophysiological testing and nonsustined ventricular tachycardia. Use and limitations in patients with coronary artery disease and impaired ventricular function. Circulation 1990; 82: 350-358.
119. Kowey PR, Taylor JE, Rials SJ, et al. Meta-analysis of the effectiveness of prophylactic drug therapy in preventing supraventricular arrhythmia early after coronary artery bypass grafting. Am J Cardiol 1992; 69:963-965.
120. Buxton AE, Simson MB, Falcone RA, et al. Results of signal-averaged electrocardiography and electrophysiologic study in patients with nonsustained ventricular tachycar-dia after healing of acute myocardial infarction. Am J Cardiol 1987; 60:80-85.
121. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia: The Multicenter Automatic Defibrillator Implantation Trial (MADIT). N Engl J Med 1996;33:1933-1940.
122. Bigger JT Jr. Prophylactic use of implantable cardioverter defiblillators: Medical, technical, economic considerations. PACE 1991; 14:376-380.
123. Nisam S, Thomas A, Mower M, et al. Identifying patients for prophylactic automatic implantable cardioverter defibrillator therapy: Status of prospective studies (editorial). Am Heart] 1991; 122:607-612.
124. Antiarrhythmics Versus Implantable Defibrillators (AVID)-Rationale, design, and methods. Am J Cardiol 1995; 75:4711-4715.
125. Buxton AE, Marchlinski FE, Flores BT, et al. Nonsustained ventricular tachycardia in patients with cornary artery disease: Role of electrophysiologic study. Circulation 1987; 75:1178-1185.
126. Klein RC, Machell C. Use of electrophysiologic testing in patients with nonsustained ventricular tachycardia: Prognostic and therapeutic implications. J Am Coll Cardiol 1989;14:155-161;discussion 162-163.
127. Richards DA, Byth K, ROSS DL, et al. What is the best predictor of spontaneous ventricular tachycardia and sudden death after myocardial infarction? Circulation 1991; 83:756-763.
128. Spielman SR, Greenspan AR, Kay HR, et al. Electrophysiologic testing in patients at high risk for sudden cardiac death. I. Nonsustained ventricular tachycardia and abnormal ventricular function. J Am Coll Cardiol 1985; 6:31-39.
129. Daubert JP, Higgins SL, Zareba W, et al. Comparative survival of MADIT-eligible but noninducible patients (abstract). J Am Coll Cardiol 1997. (In press).